🇺🇸 LENALIDOMIDE in United States

33,448 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 5,986 reports (17.9%)
  2. Diarrhoea — 4,333 reports (12.95%)
  3. Pneumonia — 3,634 reports (10.86%)
  4. Plasma Cell Myeloma — 3,629 reports (10.85%)
  5. Fatigue — 3,589 reports (10.73%)
  6. Death — 2,789 reports (8.34%)
  7. Neutropenia — 2,698 reports (8.07%)
  8. Rash — 2,525 reports (7.55%)
  9. Thrombocytopenia — 2,151 reports (6.43%)
  10. Drug Ineffective — 2,114 reports (6.32%)

Source database →

LENALIDOMIDE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is LENALIDOMIDE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for LENALIDOMIDE in United States?

Marketing authorisation holder not available in our data.